Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $103.62 Average Price Target from Analysts

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) have been given an average rating of “Moderate Buy” by the fifteen ratings firms that are currently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $103.62.

Several research analysts have recently weighed in on ITCI shares. JPMorgan Chase & Co. lifted their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. Leerink Partnrs cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Piper Sandler restated a “neutral” rating and set a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, StockNews.com started coverage on shares of Intra-Cellular Therapies in a report on Saturday, February 8th. They issued a “hold” rating on the stock.

Insider Transactions at Intra-Cellular Therapies

In other news, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Intra-Cellular Therapies

A number of large investors have recently made changes to their positions in ITCI. Handelsbanken Fonder AB boosted its stake in shares of Intra-Cellular Therapies by 23.5% during the 3rd quarter. Handelsbanken Fonder AB now owns 26,300 shares of the biopharmaceutical company’s stock worth $1,924,000 after purchasing an additional 5,000 shares during the period. CWM LLC boosted its stake in shares of Intra-Cellular Therapies by 867.5% during the 3rd quarter. CWM LLC now owns 13,274 shares of the biopharmaceutical company’s stock worth $971,000 after purchasing an additional 11,902 shares during the period. Inspire Investing LLC boosted its stake in shares of Intra-Cellular Therapies by 10.4% during the 3rd quarter. Inspire Investing LLC now owns 5,606 shares of the biopharmaceutical company’s stock worth $410,000 after purchasing an additional 528 shares during the period. Essex Investment Management Co. LLC boosted its stake in shares of Intra-Cellular Therapies by 85.7% during the 3rd quarter. Essex Investment Management Co. LLC now owns 58,385 shares of the biopharmaceutical company’s stock worth $4,272,000 after purchasing an additional 26,937 shares during the period. Finally, nVerses Capital LLC purchased a new position in shares of Intra-Cellular Therapies during the 3rd quarter worth about $285,000. 92.33% of the stock is owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Price Performance

Shares of Intra-Cellular Therapies stock opened at $127.97 on Friday. The company’s fifty day simple moving average is $103.22 and its 200-day simple moving average is $86.99. The stock has a market capitalization of $13.61 billion, a PE ratio of -147.09 and a beta of 0.72. Intra-Cellular Therapies has a 1-year low of $62.78 and a 1-year high of $128.00.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.